NCT01559831

Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination

Immune Responses to Revaccination After Potentially Insufficient Priming With the Japanese Encephalitis Vaccine IXIARO Batch JEV09L37

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Valneva Austria GmbH · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

IC51-319 is a single-arm, open-label study that investigates immune responses in subjects undergoing revaccination after receiving the subpotent batch of IXIARO JEV09L37 during primary immunization.

Detailed description

IC51-319 is a single-arm, open-label study that investigates immune responses in subjects undergoing revaccination after receiving the subpotent batch of IXIARO JEV09L37 during primary immunization. A total of up to 50 subjects having received primary immunization of IXIARO batch JEV09L37 and who have not yet been revaccinated.

Conditions

• Japanese Encephalitis

Interventions

Type	Name	Description
BIOLOGICAL	IXIARO	Vero-cell derived Japanese encephalitis (JE) vaccine IXIARO, 0.5 ml intramuscular

Timeline

• Start date: 2012-06-01
• Primary completion: 2012-12-01
• Completion: 2013-03-01
• First posted: 2012-03-21
• Last updated: 2013-03-08

Locations

1 site across 1 country: United Kingdom